Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: Role of nucleosides in the flanking sequences

Journal of Medicinal Chemistry

Volumn 45, Issue 20, 2002, Pages 4540-4548

  Yu, Dong ^a   Kandimalla, Ekambar R ^a   Cong, Yanping ^a   Tang, Jimmy ^a   Tang, Jin Yan ^a   Zhao, Qiuyan ^a   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOBUTYRIC ACID DERIVATIVE; DEOXYRIBONUCLEOSIDE; ETHYLENE GLYCOL DERIVATIVE; GLYCEROL DERIVATIVE; INTERLEUKIN 12; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROPANEDIOL DERIVATIVE; SYNTHETIC DNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA BASE COMPOSITION; DNA FLANKING REGION; DRUG DESIGN; DRUG SYNTHESIS; IMMUNOSTIMULATION; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SPLEEN CELL; STRUCTURE ACTIVITY RELATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL DIVISION; CELLS, CULTURED; CPG ISLANDS; DEOXYRIBONUCLEOSIDES; DNA; ETHYLENE GLYCOL; INTERLEUKINS; LYMPHOCYTES; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES; ORGAN SIZE; SPLEEN; SPLENOMEGALY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037179614     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0201619     Document Type: Article

References (37)

1. Tokunaga, T.; Yamamoto, H.; Shimada S.; Abe, H.; Fukuda, T.; Fujisawa, Y.; Furutani, Y.; Yano, O.; Kataoka, T.; Sudo, T.; Makiguchi, N.; Suganuma, T. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 1984, 72, 955-962.
2. Messina, J. P.; Gilkeson, G. S.; Pisetsky, D. S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 1991, 147, 1759-1764.
3. Krieg, A. M.; Yi, A. K.; Matson, S.; Waldschmidt, T. J.; Bishop, G. A.; Teasdale, R.; Koretzky, G. A.; Klinman, D. M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374, 546-549.
4. Sato, Y.; Roman, M.; Tighe, H.; Lee, D.; Corr, M.; Nguyen, M. D.; Silverman, G. J.; Lotz, M.; Carson, D. A.; Raz, E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273, 352-354.
5. Gurunathan, S.; Klinman, D. M.; Seder, R. A. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 2000, 18, 927-974.
6. Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20, 709-760.
7. Wagner, H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr. Opin. Microbiol. 2002, 5, 62-69.
8. Agrawal, S.; Kandimalla, E. R. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol. Med. 2002, 8, 114-121.
9. Agrawal, S.; Kandimalla, E. R. Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr. Cancer Drug Targets 2001, 1, 197-209.
10. Verthelyi, D.; Kenney, R. T.; Seder, R. A.; Gam, A. A.; Friedag, B.; Klinman, D. M. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J. Immunol. 2002, 168, 1659-1663.
11. Miconnet, I.; Koenig, S.; Speiser, D.; Krieg, A. M.; Guillaume, P.; Cerottini, J. C.; Romero, P. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. 2002, 168, 1212-1218.
12. Decker, T.; Hipp, S.; Kreitman, R. J.; Pastan, I.; Peschel, C.; Licht, T. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood 2002, 99, 1320-1326.
13. Warren, T. L.; Weiner, G. J. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma. Semin Oncol 2002, 29 (1, Suppl. 2), 93-97.
14. Al-Mariri, A.; Tibor, A.; Mertens, P.; De Bolle, X.; Michel, P.; Godfroid, J.; Walravens, K.; Letesson, J. J. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynuclotides as adjuvant. Infect. Immun. 2001, 69, 4816-4822.
15. Gramzinski, R. A.; Doolan, D. L.; Sedegah, M.; Davis, H. L.; Krieg, A. M.; Hoffman, S. L. Interleukin-12- and γ-interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect. Immun. 2001, 69, 1643-1649.
16. Kovarik, J.; Bozzotti, P.; Tougne, C.; Davis, H. L.; Lambert, P. H.; Krieg, A. M.; Siegrist, C. A. Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens. Immunology 2001, 102, 67-76.
17. Hochreiter, R.; Hartl, A.; Freund, J.; Valenta, R.; Ferreira, F.; Thalhamer, J. The influence of CpG motifs on a protein or DNA-based Th2-type immune response against major pollen allergens Bet v 1a, Phl p 2 and Escherichia coli-derived beta-galactosidase. Int. Arch. Allergy Immunol. 2001, 124, 406-410.
18. Blazar, B. R.; Krieg, A. M.; Taylor, P. A. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood 2001, 98, 1217-1225.
19. Tighe, H.; Takabayashi, K.; Schwartz, D.; Van Nest, G.; Tuck, S.; Eiden, J. J.; Kagey-Sobotka, A.; Creticos, P. S.; Lichtenstein, L. M.; Spiegelberg, H. L.; Raz, E. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 2000, 106, 124-134.
20. Tokunaga, T.; Yano, O.; Kuramoto, E.; Kimura, Y.; Yamamoto, T.; Kataoka, T.; Yamamoto, S. Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol. Immunol. 1992, 36, 55-66.
21. Yamamoto, T.; Yamamoto, S.; Kataoka, T.; Tokunaga, T. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res. Dev. 1994, 4, 119-122.
22. Zhao, Q.; Temsamani, J.; Iadarola, P. L.; Jiang, Z.; Agrawal, S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem. Pharmacol. 1996, 51, 173-182.
23. Zhao, Q.; Yu, D.; Agrawal, S. Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg. Med. Chem. Lett. 1999, 9, 3453-3458.
24. Zhao, Q.; Yu, D.; Agrawal, S. Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorg. Med. Chem. Lett. 2000, 10, 1051-1054.
25. Yu, D.; Kandimalla, E. R.; Zhao, Q.; Cong, Y.; Agrawal, S. Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg. Med. Chem. 2001, 9, 2803-2808.
26. Yu, D.; Zhao, Q.; Kandimalla, E. R.; Agrawal, S. Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg. Med. Chem. Lett. 2000, 10, 2585-2588.
27. Kandimalla, E. R.; Yu, D.; Zhao, Q.; Agrawal, S. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg. Med. Chem. 2001, 9, 807-813.
28. Yu, D.; Kandimalla, E. R.; Zhao, Q.; Cong, Y.; Agrawal, S. Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg. Med. Chem. Lett. 2001, 11, 2263-2267.
29. Yu, D.; Kandimalla, E. R.; Zhao, Q.; Cong, Y.; Agrawal, S. Immunostimulatory properties of phosphorothioate CpG DNA containing both 3′-5′- and 2′-5′-internucleotide linkages. Nucleic Acids Res. 2002, 30, 1613-1619.
30. Branda, R. F.; Moore, A. L.; Mathews, L.; McCormack, J. J.; Zon, G. Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem. Pharmacol. 1993, 45, 2037-2043.
31. Kandimalla, E. R.; Yu, D.; Agrawal, S. Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr. Opin. Mol. Ther. 2002, 4, 122-129.
32. Spiegelberg, H. L.; Raz, E. DNA-based approaches to the treatment of allergies. Curr. Opin. Mol. Ther. 2002, 4, 64-71.
33. Temsamani, J.; Tang, J. Y.; Agrawal, S. Capped oligodeoxynucleotide phosphorothioates. Pharmacokinetics and stability in mice. Ann. N.Y. Acad. Sci. 1992, 660, 318-320.
34. Temsamani, J.; Tang, J. Y.; Padmapriya, A.; Kubert, M.; Agrawal, S. Pharmacokinetics, biodistribution, and stability of capped oligodeoxynucleotide phosphorothioates in mice. Antisense Res. Dev. 1993, 3, 277-284.
35. Levis, J. T.; Miller, P. S. Properties of exonuclease-resistant, psoralen-conjugated oligodeoxyribonucleotides in vitro and in cell culture. Antisense Res Dev. 1994, 4, 231-241.
36. Pandolfi, D.; Rauzi, F.; Capobianco, M. L. Evaluation of different types of end- capping modifications on the stability of oligonucleotides toward 3′- and 5′-exonucleases. Nucleosides Nucleotides 1999, 18, 2051-2069.
37. Iyer, R. P.; Eagan, W.; Regan, J. B.; Beaucage, S. L. 3H-1,2-benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyrionucleoside phosphorothioates. J. Am. Chem. Soc. 1990, 112, 1253-1254.